- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
New York State Common Retirement Fund Reduces Gilead Sciences Stake
The institutional investor sold 89,400 shares of the biopharmaceutical company's stock in the third quarter.
Jan. 29, 2026 at 8:47am
Got story updates? Submit your updates here. ›
New York State Common Retirement Fund, a major institutional investor, reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% in the third quarter, according to a recent 13F filing with the Securities & Exchange Commission. The fund now owns 1,472,917 shares of the biopharmaceutical company's stock, worth approximately $163.5 million.
Why it matters
Gilead Sciences is a prominent biopharmaceutical company known for its antiviral therapies, particularly in the areas of HIV and viral hepatitis. The reduction in stake by a major institutional investor like the New York State Common Retirement Fund could signal a shift in sentiment or investment strategy around the company.
The details
According to the 13F filing, the New York State Common Retirement Fund sold 89,400 shares of Gilead Sciences during the third quarter. The fund now owns approximately 0.12% of the company's outstanding shares. The sale comes as Gilead Sciences continues to navigate the competitive landscape in its core therapeutic areas and explore new opportunities in oncology, cell therapy, and inflammatory diseases.
- The 13F filing was submitted on January 29, 2026, covering the third quarter of 2025.
The players
New York State Common Retirement Fund
A major institutional investor that manages a pension fund for New York state employees.
Gilead Sciences, Inc.
A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, including antiviral therapies, oncology, cell therapy, and inflammatory diseases.
The takeaway
The reduction in stake by the New York State Common Retirement Fund, a prominent institutional investor, could signal a shift in sentiment or investment strategy around Gilead Sciences. As the company navigates the competitive landscape in its core therapeutic areas and explores new opportunities, investors will be closely watching its performance and strategic direction.
